Showing 8541-8550 of 10813 results for "".
- Rituximab Efficacious for Epidermolysis Bullosa Acquisita: Analysishttps://practicaldermatology.com/news/rituximab-shows-promise-for-epidermolysis-bullosa-acquisita/2473835/Data from a new systematic review indicate rituximab (RTX) may potentially be an effective treatment option for epidermolysis bullosa acquisita (EBA). Due to its chronic nature, management of EBA remains challenging, with remission and flare-up
- Analysis: 3D Imaging Yields Higher Costs Without Detection Benefit in High-Risk Melanoma Patientshttps://practicaldermatology.com/news/analysis-3d-imaging-and-telederm-higher-costs-without-significant-detection-benefit-in-high-risk-melanoma-patients/2471858/New research indicates 3D total-body photography (TBP) paired with sequential digital dermoscopy imaging (SDDI) leads to higher care costs without significantly improving the detection of malignant melanomas when compared to usual care for high-risk patients. <
- Lipid Metabolites Linked to Atopic Dermatitis Riskhttps://practicaldermatology.com/news/lipid-metabolites-linked-to-atopic-dermatitis-risk/2471714/A two-sample Mendelian randomization (TSMR) study has identified 13 lipid-related metabolite traits that influence the risk of developing atopic dermatitis (AD). Researchers examined genome-wide association study (GWAS) datase
- From AAD: What's New in Acne and Rosacea?https://practicaldermatology.com/news/from-aad-whats-new-in-acne-and-rosacea/2471565/Dermatologists gathered for the Acne and Rosacea session at the 2025 American Academy of Dermatology in Orlando conference were treated to comprehensive updates on two prevalent skin conditions—acne and rosacea—presented by Julie Harper, MD, and Hilary Baldwin, MD,
- Charlotte Dermatology, DOCS Dermatology Group Partner, With PGP as Advisorhttps://practicaldermatology.com/news/Charlotte-Dermatology-DOCS-Dermatology-Group-Partner-With-PGP-Advisor/2471624/Physician Growth Partners (PGP) announced it recently advised Charlotte Dermatology on its partnership with DOCS Dermatology Group (backed by SkyKnight Capital). Founded in 1939, Charlotte Dermatology is one of the longest-standing and most trusted dermatology practices in the Greater Char
- Further Positive Delgocitinib Data Presented at AADhttps://practicaldermatology.com/news/Further-Positive-Delgocitinib-Data-Presented-AAD/2471609/Late-breaking data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showcased responses in a subgroup of patients from the DELTA 1 and Delta 2 trials on lebrikizumab for chronic hand eczema. Alongside this presentation, new systemic exposure
- New Baricitinib AA Data for Adolescents Could Be 'Game-Changing'https://practicaldermatology.com/news/New-Baricitinib-AA-Data-Adolescents-Could-Be-Game-Changing/2471600/Patients ages 12 to under 18 with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36 in the Phase 3 BRAVE-AA-PEDS study, presented as a late-breaker at the 202
- Report: L'Oreal Recalling BPO Product Due to Benzenehttps://practicaldermatology.com/news/Report-LOreal-Recalling-BPO-Product-Due-Benzene/2471598/L’Oreal SA is recalling La Roche-Posay’s benzoyl peroxide acne treatment, Effaclar Duo, in the US because of “concern that the creams are contaminated with benzene,” Bloomberg News reported. L’Oreal said testing found trace levels of benzene in one lot product, according to Bloomberg.
- From Tattoos to Virtual Tools: A Look at the Technology Transforming Hair Clinicshttps://practicaldermatology.com/news/from-tattoos-to-virtual-tools-a-look-at-the-technology-transforming-hair-clinics/2471548/
- Promoting Pigmentation and Preventing Relapses Highlighted as Keys in Vitiligo Treatmenthttps://practicaldermatology.com/news/Promoting-Pigmentation-Preventing-Relapses-Highlighted-Keys-Vitiligo-Treatment/2471550/The way practitioners diagnose and manage vitiligo patients continues to advance with recent discoveries in the pathogenesis, risk factors, and features of the disease activity. At the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, one discussion focused on pattern